Earnings results for InMed Pharmaceuticals (NASDAQ:INM)
InMed Pharmaceuticals Inc. is estimated to report earnings on 08/26/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.34.
Analyst Opinion on InMed Pharmaceuticals (NASDAQ:INM)
1 Wall Street analysts have issued ratings and price targets for InMed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.50, predicting that the stock has a possible upside of 422.73%. The high price target for INM is $11.50 and the low price target for INM is $11.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
InMed Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.50, InMed Pharmaceuticals has a forecasted upside of 422.7% from its current price of $2.20. InMed Pharmaceuticals has received no research coverage in the past 90 days.
Dividend Strength: InMed Pharmaceuticals (NASDAQ:INM)
InMed Pharmaceuticals does not currently pay a dividend. InMed Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: InMed Pharmaceuticals (NASDAQ:INM)
In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock. Only 5.21% of the stock of InMed Pharmaceuticals is held by institutions.
Earnings and Valuation of InMed Pharmaceuticals (NASDAQ:INM
Earnings for InMed Pharmaceuticals are expected to grow in the coming year, from ($1.44) to ($1.00) per share.
More latest stories: here